{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:21:25Z","timestamp":1761218485616,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Creutzfeldt\u2013Jakob disease (CJD) is a rare form of rapidly progressive, neurodegenerative disease that results from the misfolding and accumulation of an aberrant, disease-associated prion protein (PrPD). CJD affects 1\u20131.5 cases per million per year with the sporadic-type accounting for an estimated 85% of these cases. Sporadic CJD (sCJD) is further subdivided into five subtypes based on genetic polymorphisms; the rarest subtype, sCJDVV1, occurs at a rate of 1 case per one-hundredth million population per year. Clinical characteristics of the sCJDVV1 subtype have been reported to show, early age of onset (44 years), average disease duration of 21 months, absent PSWCs on electroencephalography (EEG), and MRI hyperintensities in the cerebral cortex with usual negative signal in the basal ganglia or thalamus. We present a case of the sCJDVV1 subtype with uncommon features. Contrary to current data on sCJDVV1, our patient presented with an unusual age at onset (61 years) and longer disease duration (32 months). The highly sensitive and specific real-time quaking-induced conversion (RT-QuIC) assay was negative. Presenting clinical symptoms included paranoid thoughts and agitation, rapidly progressive memory decline, prosopagnosia, and late development of myoclonus and mutism. Other findings showed positive antithyroid peroxidase antibodies (anti-TPO), and absent PSWCs on EEG. High-dose steroid therapy treatment was administered based on positive anti-TPO findings, which failed to elicit any improvement and the patient continued to decline. To our knowledge, only four cases with the sCJDVV1 subtype, including our patient, have been reported to have a negative result on RT-QuIC. This may suggest varied sensitivity across sCJD subtypes. However, given the rarity of our patient's subtype, and the relatively novel RT-QuIC, current data are based on a small number of cases and larger cohorts of confirmed VV1 cases with RT-QuIC testing need to be reported.<\/jats:p>","DOI":"10.3389\/fneur.2022.875370","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T06:36:32Z","timestamp":1652078192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Atypical Case of VV1 Creutzfeldt\u2013Jakob Disease Subtype: Case Report"],"prefix":"10.3389","volume":"13","author":[{"given":"Adrianna E.","family":"Carrasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Appleby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignazio","family":"Cali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid R.","family":"Okhravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"B1","unstructured":"Creutzfeldt-Jakob Disease, Classic: About CJD Center for Disease Control and Prevention.2021"},{"key":"B2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.55782\/ane-2002-1434","article-title":"Molecular biology of prions","volume":"62","author":"Weissmann","year":"2002","journal-title":"Acta Neurobiol Exp."},{"key":"B3","doi-asserted-by":"publisher","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","article-title":"Prions","volume":"95","author":"Prusiner","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1007\/BF01716575","article-title":"Die histopathologische forschung in der psychiatrie","volume":"1","author":"Spielmeyer","year":"1922","journal-title":"Klin Wochenschr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ana.410390613","article-title":"Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease","volume":"39","author":"Parchi","year":"1996","journal-title":"Ann Neurol."},{"key":"B6","first-page":"224","article-title":"Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects","volume-title":"Ann Neurol","author":"Parchi","year":"1999"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41598-020-58446-0","article-title":"Co-existence of PrP(D) types 1 and 2 in sporadic Creutzfeldt-Jakob disease of the VV subgroup: phenotypic and prion protein characteristics","volume":"10","author":"Cali","year":"2020","journal-title":"Sci Rep."},{"article-title":"Creutzfeldt Jakob Disease","year":"2021","author":"Sitammagari","key":"B8"},{"key":"B9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/bmb\/66.1.213","article-title":"Sporadic and familial CJD: classification and characterisation","volume":"66","author":"Gambetti","year":"2003","journal-title":"Br Med Bull."},{"key":"B10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00401-010-0779-6","article-title":"Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future","volume":"121","author":"Parchi","year":"2011","journal-title":"Acta Neuropathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(12)70063-7","article-title":"Sporadic human prion diseases: molecular insights and diagnosis","volume":"11","author":"Puoti","year":"2012","journal-title":"Lancet Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1212\/01.wnl.0000184674.32924.c9","article-title":"Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type","volume":"65","author":"Meissner","year":"2005","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1017","DOI":"10.1212\/WNL.0000000000010086","article-title":"Diagnosis of prion diseases by RT-QuIC results in improved surveillance","volume":"95","author":"Rhoads","year":"2020","journal-title":"Neurology."},{"year":"2003","key":"B14","article-title":"including variant Creutzfeldt-Jakob disease"},{"key":"B15","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2015.8.FOCUS15328","article-title":"Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy","volume":"39","author":"Manix","year":"2015","journal-title":"Neurosurg Focus."},{"key":"B16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.clineuro.2008.09.017","article-title":"An unusually presenting case of sCJD\u2013the VV1 subtype","volume":"111","author":"Tanev","year":"2009","journal-title":"Clin Neurol Neurosurg."},{"key":"B17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/v13050789","article-title":"Clinical use of improved diagnostic testing for detection of prion disease","volume":"13","author":"Figgie MP","year":"2021","journal-title":"Viruses"},{"key":"B18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1001\/archneur.63.6.876","article-title":"Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease","volume":"63","author":"Krasnianski","year":"2006","journal-title":"Arch Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaneurol.2020.1319","article-title":"Evaluation of a New Criterion for Detecting Prion Disease With Diffusion Magnetic Resonance Imaging","volume":"77","author":"Bizzi","year":"2020","journal-title":"JAMA Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/WAD.0b013e31818323ef","article-title":"Correlating DWI MRI with pathologic and other features of Jakob-Creutzfeldt disease","volume":"23","author":"Geschwind","year":"2009","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1148\/rg.2017160075","article-title":"Imaging of Creutzfeldt-Jakob Disease: Imaging Patterns and Their Differential Diagnosis","volume":"37","author":"Fragoso","year":"2017","journal-title":"Radiographics."},{"key":"B22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.nicl.2014.01.011","article-title":"Application of quantitative DTI metrics in sporadic CJD","volume":"4","author":"Caverzasi","year":"2014","journal-title":"Neuroimage Clin."},{"key":"B23","doi-asserted-by":"publisher","first-page":"102523","DOI":"10.1016\/j.nicl.2020.102523","article-title":"Multimodal MRI staging for tracking progression and clinical-imaging correlation in sporadic Creutzfeldt-Jakob disease","volume":"30","author":"Sacco","year":"2021","journal-title":"Neuroimage Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s13760-018-0995-8","article-title":"A systematic review comparing the diagnostic value of 14-3-3 protein in the cerebrospinal fluid, RT-QuIC and RT-QuIC on nasal brushing in sporadic Creutzfeldt-Jakob disease","volume":"118","author":"Behaeghe","year":"2018","journal-title":"Acta Neurol Belg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/ane.12441","article-title":"CSF tau correlates with CJD disease severity and cognitive decline","volume":"133","author":"Cohen","year":"2016","journal-title":"Acta Neurol Scand."},{"key":"B26","doi-asserted-by":"publisher","first-page":"585896","DOI":"10.3389\/fbioe.2020.585896","article-title":"Challenges and Advances in Antemortem Diagnosis of Human Transmissible Spongiform Encephalopathies","volume":"8","author":"Ascari","year":"2020","journal-title":"Front Bioeng Biotechnol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13195-017-0331-1","article-title":"The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias","volume":"10","author":"Abu-Rumeileh","year":"2018","journal-title":"Alzheimers Res Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/ene.13389","article-title":"Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort","volume":"24","author":"Kovacs","year":"2017","journal-title":"Eur J Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1136\/jnnp-2020-323826","article-title":"Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease","volume":"91","author":"Abu-Rumeileh","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/practneurol-2018-001935","article-title":"RT-QuIC: a new test for sporadic CJD","volume":"19","author":"Green","year":"2019","journal-title":"Pract Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ana.23589","article-title":"Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease","volume":"72","author":"McGuire","year":"2012","journal-title":"Ann Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/brain\/awl159","article-title":"Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease","volume":"129","author":"Collins","year":"2006","journal-title":"Brain"},{"key":"B33","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fneur.2018.00242","article-title":"Early-Onset Creutzfeldt-Jakob Disease Mimicking Immune-Mediated Encephalitis","volume":"9","author":"Wiels","year":"2018","journal-title":"Front Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00401-017-1683-0","article-title":"Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Abeta42 levels","volume":"133","author":"Lattanzio","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ana.24833","article-title":"Diagnostic and prognostic value of human prion detection in cerebrospinal fluid","volume":"81","author":"Foutz","year":"2017","journal-title":"Ann Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e00769","DOI":"10.1128\/JCM.00769-19","article-title":"Clinical laboratory tests used to aid in diagnosis of human prion disease","volume":"57","author":"Connor","year":"2019","journal-title":"J Clin Microbiol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40478-020-00990-x","article-title":"Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids","volume":"8","author":"Candelise","year":"2020","journal-title":"Acta Neuropathol Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/crad.2001.0771","article-title":"of Creutzfeldt-Jakob disease: imaging features and recommended MRI protocol","volume":"56","author":"Collie","year":"2001","journal-title":"Clin Radiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ana.25983","article-title":"Subtype Diagnosis of Sporadic Creutzfeldt-Jakob Disease with Diffusion Magnetic Resonance Imaging","volume":"89","author":"Bizzi","year":"2021","journal-title":"Ann Neurol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.coph.2018.11.006","article-title":"Therapeutic strategies for prion disease: a practical perspective","volume":"44","author":"Appleby","year":"2019","journal-title":"Curr Opin Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e131175","DOI":"10.1172\/jci.insight.131175","article-title":"Antisense oligonucleotides extend survival of prion-infected mice","volume":"5","author":"Raymond","year":"2019","journal-title":"JCI Insight"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","article-title":"Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints","volume":"48","author":"Minikel","year":"2020","journal-title":"Nucleic Acids Res."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.875370\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T03:08:18Z","timestamp":1727147298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.875370\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":42,"alternative-id":["10.3389\/fneur.2022.875370"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.875370","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"article-number":"875370"}}